Systematically Testing the Evidence on Marijuana
Registered Ongoing Studies
The STEM research team developed this section for researchers to browse cannabis-related registered ongoing studies from the US National Library for Medicine’s ClinicalTrials.gov site. We have highlighted some areas of interest below, but additional topics (e.g., other autoimmune disorders, epilepsy, cannabis-related effects) can be explored by selecting filters below. Please note many studies may appear in more than one category. We encourage you to share your feedback or suggestions.
Search Results (1674)
Page: << < 1 2 [3] 4 5 6 7 8 > >>Cannabidiol for Reducing Drinking in Alcohol Use Disorder
The non-psychotomimetic cannabis compound cannabidiol (CBD) has been found effective for reducing alcohol drinking in mice. Moreover, other experimental studies have found that CBD reduced alcohol-induced steatosis in the liver, and reduced alcohol-related injury in the brain. Despite these promising results from animal data, no human study has been conducted yet in alcohol use disorder (AUD).
First Posted: December 16, 2021
Condition(s): Alcohol Use Disorder
Intervention(s): Cannabidiol Cap/Tab, Placebo Cap/Tab
Status: Not yet recruiting
Enrollment (expected or actual): 76
Allocation: Randomized
Sponsor: Hôpital le Vinatier
Principal Investigator:
Completion Date (primary or actual): September 30, 2024
CT.gov Identifier: NCT05159830
Effect of Extended Cannabis Abstinence on PTSD Symptoms
This will be a 12-week randomized trial. Outpatients and patients from the Mood and Anxiety program at the Centre for Addiction and Mental Health (CAMH) with a current diagnosis of post-traumatic stressed disorder (PTSD) and cannabis-use disorder (CUD) will be randomized to receive individual motivational interviewing therapy and contingency management (n = 12) or individual motivational interviewing therapy alone (control group, n = 12) after enrolment.
First Posted: December 17, 2021
Condition(s): PTSD, Cannabis Use, Cognitive Symptom, Comorbidities and Coexisting Conditions
Intervention(s): Contingency-management, Enhanced usual care
Status: Recruiting
Enrollment (expected or actual): 24
Allocation: Randomized
Sponsor: Centre for Addiction and Mental Health
Principal Investigator: Ahmed N Hassan, Doctor
Completion Date (primary or actual): September 1, 2023
CT.gov Identifier: NCT05162651
Enhancing Prolonged Exposure With Cannabidiol to Treat Posttraumatic Stress Disorder
The primary goal of this pilot project is to demonstrate the safety and feasibility of using Cannabidiol (CBD) in combination with standard of care prolonged exposure (PE) psychotherapy to reduce PTSD symptoms.
First Posted: November 24, 2021
Condition(s): Posttraumatic Stress Disorder, Stress Disorders, Post-Traumatic
Intervention(s): Cannabidiol (CBD) oral solution, Placebo, Massed Prolonged Exposure (mPE)
Status: Recruiting
Enrollment (expected or actual): 28
Allocation: Randomized
Sponsor: The University of Texas Health Science Center at San Antonio
Principal Investigator: Casey Straud, Assistant Professor
Completion Date (primary or actual): January 2023
CT.gov Identifier: NCT05132699
Detecting Drugs of Abuse Via Exhaled Breath Samples Using Differential Mobility Spectrometry
This Phase II STTR program consists of two major goals within the overarching goal of developing and validating a proprietary device (BID2) for marijuana and opioid detection in breath samples.
First Posted: May 20, 2022
Condition(s): Opiate Abuse, Marijuana Abuse
Intervention(s): Marihuana, BID2 Instrument - breathalyzer
Status: Recruiting
Enrollment (expected or actual): 50
Allocation: N/A
Sponsor: Mclean Hospital
Principal Investigator: Scott Lukas, Scott Lukas, Ph.D.
Completion Date (primary or actual): June 30, 2023
CT.gov Identifier: NCT05384470
A Study to Investigate the Bioavailability and Skin Absorption of CBD and THC From GT4 Technology in Healthy Adults
The bioavailability of cannabinoids differs greatly for different routes of administration. When applied topically to the skin, they are absorbed through the skin or hair follicles while interacting with receptors to provide localized effects. To gain more information on the potential of this route of administration in therapeutic applications, this open-label study will investigate the skin absorption and bioavailability of CBD and THC delivered trans-dermally.
First Posted: November 16, 2021
Condition(s): Biological Availability, Skin Absorption, CBD, THC
Intervention(s): CBD and THC with GT4 technology
Status: Recruiting
Enrollment (expected or actual): 18
Allocation: N/A
Sponsor: Gefion Canada Inc.
Principal Investigator:
Completion Date (primary or actual): March 2022
CT.gov Identifier: NCT05121506
Evaluation of the Interactions of Cannabidiol (CBD) With Morphine
The purpose of this study is to analyze drug-drug interactions of CBD on co-administered Morphine as first step in understanding CBD-opioid interactions.
First Posted: December 3, 2021
Condition(s): Opioid Use Disorder
Intervention(s): Morphine Sulfate
Status: Recruiting
Enrollment (expected or actual): 60
Allocation: Non-Randomized
Sponsor: National Institute on Drug Abuse (NIDA)
Principal Investigator:
Completion Date (primary or actual): September 1, 2022
CT.gov Identifier: NCT05143424
THC Memory & Reward Learning Pilot
Tetrahydrocannabidiol (THC) is the psychoactive chemical in cannabis that makes people high. This study aims to dissect acute impairment of various forms of memory and learning by THC in cannabis compared to placebo. Impairment will be assessed via a short cognitive test battery and then subjects will complete four tasks in the fMRI scanner.
First Posted: November 11, 2021
Condition(s): Marijuana, THC, Cannabis
Intervention(s): Marijuana, Hash, THC, or Grass, Placebo
Status: Not yet recruiting
Enrollment (expected or actual): 20
Allocation: Randomized
Sponsor: Hartford Hospital
Principal Investigator: Godfrey Pearlson, Founding Director Olin Neuropsychiatry Research Center; Professor Yale University
Completion Date (primary or actual): February 2024
CT.gov Identifier: NCT05116527
Fire Dragon Pot Moxibustion
Insomnia in perimenopausal women is normal. Studies have shown that insomnia occurs in 75-81% of perimenopausal women and is 2.4 times more common than in premenopausal participants. Western medicine often uses sedative sleeping drugs in the treatment of insomnia in perimenopausal women, which have better effects but have more side effects, and whether they are suitable for long-term application is still controversial. Non-pharmacological traditional therapies in Traditional Chinese Medicine have achieved significant clinical efficacy in the treatment of perimenopausal insomnia patients in recent years. This study aims to explore the efficacy of auricular point seed burying combined with fire dragon pot moxibustion in the treatment of the insomnia symptoms of perimenopausal women.
First Posted: February 10, 2022
Condition(s): Insomnia, Perimenopause
Intervention(s): Traditional Chinese Medicine auricular acupuncture point buried seeds therapy plus the fire dragon pot moxibustion therapy., Traditional Chinese Medicine auricular acupuncture point buried seeds therapy
Status: Completed
Enrollment (expected or actual): 70
Allocation: Randomized
Sponsor: Weihua Yu
Principal Investigator: Weihua Yu, Director of nursing department
Completion Date (primary or actual): October 30, 2020
CT.gov Identifier: NCT05234814
Standardized Field Test for Marijuana Impairment II
This research responds to NHTSA's request with a proposal to increase our understanding of smoked cannabis' (CNB's) acute effects on driving-relevant cognition and simulated driving performance, the persistence of these deficits over the hours after use, and the influence of prior experience with CNB on these effects. This extension study will aim to further investigate marijuana impaired behavior, using a similar design to our previous NHTSA Examine the Feasibility of a Standardized Field Test for Marijuana Impairment and the prior NIDA Neuroscience of Marijuana-Impaired Driving award, that used similar techniques and measures to quantify marijuana impaired automobile driving. We will be utilizing tasks and assessments that were shown to be strong indicators for cognitive and driving impairment in our NHTSA study.
First Posted: November 10, 2021
Condition(s): Marijuana Impairment
Intervention(s): Medium THC, Placebo THC
Status: Not yet recruiting
Enrollment (expected or actual): 32
Allocation: Non-Randomized
Sponsor: Yale University
Principal Investigator: Godfrey Pearlson, Professor of Psychiatry and Neuroscience, Founding Director Olin Neuropsychiatry Research Center
Completion Date (primary or actual): February 2024
CT.gov Identifier: NCT05115513
The Effect of Medical Cannabis on Tics, Premonitory Urge and Psychiatric Comorbidity in Adults With Tourette Syndrome
Medical cannabis (MC) is a standard treatment in Israel to adults with resistant Gilles de la Tourette syndrome (GTS). While small randomized control trials assessed THC efficacy on tics and premonitory urge, only small retrospective studies assessed MC efficacy and tolerability in GTS. Herein, By using an open-label, prospective design, our aim is to determine the preferred method of use, efficacy and tolerability of 12 weeks of treatment with MC in adult patients with GTS.
First Posted: November 10, 2021
Condition(s): Tourette Syndrome, Cannabis
Intervention(s): Medical Cannabis
Status: Completed
Enrollment (expected or actual): 18
Allocation:
Sponsor: Tel-Aviv Sourasky Medical Center
Principal Investigator:
Completion Date (primary or actual): March 31, 2021
CT.gov Identifier: NCT05115318
Vaped Marijuana to Attenuate Naloxone-Precipitated Withdrawal
The goal of the proposed, proof-of-concept study is to test the combined effects of vaporized marijuana [Delta-9-tetrahydracannabinol (THC)] with NLX as a proof of concept towards the possible development of a combined overdose reversal agent with improved tolerability.
First Posted: November 10, 2021
Condition(s): Opioid Overdose
Intervention(s): Naloxone, Marijuana
Status: Recruiting
Enrollment (expected or actual): 32
Allocation: Randomized
Sponsor: New York State Psychiatric Institute
Principal Investigator: Jermaine Jones, Principal Investigator
Completion Date (primary or actual): September 30, 2023
CT.gov Identifier: NCT05114460
Cannabis Use Patterns Among Cancer Patients
This study determines patterns of cannabis use among cancer patients. Information collected in this study may help doctors to understand patient use of cannabis therapy, their knowledge and experiences with this therapy, benefits and risks associated with its use, and whether or to what extent they are discussing it with their health care providers.
First Posted: November 24, 2021
Condition(s): Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Intervention(s): Survey Administration
Status: Recruiting
Enrollment (expected or actual): 1000
Allocation:
Sponsor: Thomas Jefferson University
Principal Investigator:
Completion Date (primary or actual): October 29, 2022
CT.gov Identifier: NCT05132842
Effect of Medical Cannabis for Non-motor Symptoms of Parkinson's Disease
Medical cannabis (MC) is a standard treatment in Israel to Parkinson's disease (PD) patients suffering from pain. Nevertheless, it is not known about MC effectiveness for other non-motor symptoms of the disease. Our aim is to prospectively observe patients with PD before and after initiation of MC, for non-motor symptoms effect. In specific, relying of data from multiple sclerosis patients and basic science showing cannabinoid receptor 1 (CB1) is abundantly expressed in the sub epithelial layer of the bladder, we will explore the impact of MC on bladder function and urinary symptoms.
First Posted: November 3, 2021
Condition(s): Bladder, Overactive, Parkinson Disease
Intervention(s): Medical Cannabis
Status: Recruiting
Enrollment (expected or actual): 100
Allocation:
Sponsor: Sheba Medical Center
Principal Investigator: Dr. Saar Anis, Principal investigator. Senior Neurologist, Movement Disorders Institute, Sheba Medical Center
Completion Date (primary or actual): August 2023
CT.gov Identifier: NCT05106504
Evaluation of Effects of CBD Products on Anxiety Among U.S. Women
The investigators will conduct a retrospective cohort analysis of a consumer trial conducted by Rae Wellness. The trial took place between October 15, 2020 and December 30, 2020 and involved 1350 U.S. women who used in-home use tests (IHUT) of various Cannabidiol (CBD) products. Participants were randomized to one of 9 groups: 8 groups received one of 8 different CBD products in the mail, and one group served as the control and did not consume any CBD product. The CBD products varied by method of delivery, concentration of Tetrahydrocannabinol (THC), and dosage of CBD. Participants were asked to use the product once daily for 60 day and to complete health questionnaires at baseline, 30 days and 60 days.
First Posted: November 4, 2021
Condition(s): Anxiety, Generalized Anxiety Disorder
Intervention(s): Cannabidiol (CBD)- containing consumer products
Status: Completed
Enrollment (expected or actual): 1350
Allocation:
Sponsor: Radicle Science
Principal Investigator:
Completion Date (primary or actual): December 30, 2020
CT.gov Identifier: NCT05108220
CBD for Sleep in People With HIV
This study will obtain preliminary information about whether, and at what dose, cannabidiol (CBD) may help with insomnia in people living with human immunodeficiency virus (HIV). The study will be a 5-week randomized, double-blind placebo-controlled phase II trial using daily oral CBD doses between 50mg and 600mg. Sleep problems will be measured using a wrist-worn device and by self-report. Performance on tests of thinking skills will be compared before and after CBD/placebo treatment. Positive study results will provide support for the use of CBD as a potential treatment for insomnia.
First Posted: October 28, 2021
Condition(s): Sleep Disturbance
Intervention(s): Cannabidiol oral solution, Inert sesame seed oil
Status: Not yet recruiting
Enrollment (expected or actual): 16
Allocation: Randomized
Sponsor: Mariana Cherner, PhD
Principal Investigator: Mariana Cherner, PhD, Professor IR
Completion Date (primary or actual): October 2023
CT.gov Identifier: NCT05097651
Cannabis and Aging
With increased availability and use of cannabis by older adults aged ≥ 50 years, a rigorous evaluation of the benefits and risks of cannabis use in these individuals is necessary. Our proposed project will investigate whether older adults who initiate cannabis use after the age of 50 are at an increased risk of fall and what are the underlying mechanisms. We will measure motor and cognitive function in older cannabis users and nonusers and we will use positron emission tomography to determine brain activity and how it is associated with fall risk.
First Posted: October 19, 2021
Condition(s): Cannabis Use
Intervention(s):
Status: Recruiting
Enrollment (expected or actual): 60
Allocation:
Sponsor: Thorsten Rudroff
Principal Investigator: Thorsten Rudroff, Associate Professor
Completion Date (primary or actual): November 1, 2021
CT.gov Identifier: NCT05084105
DIalysis Symptom COntrol-Pruritus Outcome Trial
The purpose of this study is to test whether or not a medication called nabilone, which is a synthetic (non-natural) medication derived from cannabis, compared to placebo improves symptoms of itch in hemodialysis as measured by visual analog scales.
First Posted: January 6, 2022
Condition(s): End Stage Renal Disease, Pruritus
Intervention(s): Nabilone 0.5 MG Oral Capsule, Placebo Nabilone
Status: Not yet recruiting
Enrollment (expected or actual): 12
Allocation: Randomized
Sponsor: University of Manitoba
Principal Investigator: David Collister, Adjunct Assistant Professor
Completion Date (primary or actual): October 2023
CT.gov Identifier: NCT05180968
Stress-Reactivity and Cannabis Use in Cannabis-Using Older Adults
The goal of the study is to evaluate how cannabis use affects memory and thinking skills and response to stress in older adults. The study will also relate cannabis use to Alzheimer's Disease (AD) biomarkers (measurable substances in blood that indicate condition), and test whether sex and hormones play a role in these effects. The study is recruiting adults between the ages of 50 and 80 who use cannabis products on a regular basis. Study participation will last about two weeks.
First Posted: October 11, 2021
Condition(s): Cannabis Use
Intervention(s): Trier Social Stress Task (TSST)
Status: Recruiting
Enrollment (expected or actual): 40
Allocation: N/A
Sponsor: Medical University of South Carolina
Principal Investigator: Andreana Benitez, Assistant Professor
Completion Date (primary or actual): August 2023
CT.gov Identifier: NCT05072795
Joint Effort Study
This pilot randomized controlled trial (RCT) will be conducted to evaluate the acceptability and feasibility of a digital tailored prevention tool (i.e., the Joint Effort mobile application) aimed at supporting university-level students into taking action on their cannabis use. The two main objectives of the proposed study are:
To assess the acceptability of the Joint Effort mobile application in terms of uptake, engagement and intervention appreciation.
To document the feasibility of the study processes in terms of online recruitment rate, adherence to online data collection methods, and attrition rate.
First Posted: October 29, 2021
Condition(s): Cannabis Use
Intervention(s): Joint Effort, Brief normative feedback and standard information
Status: Recruiting
Enrollment (expected or actual): 70
Allocation: Randomized
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
Principal Investigator:
Completion Date (primary or actual): April 2022
CT.gov Identifier: NCT05099016
Cannabis as a Complementary Treatment in Multiple Sclerosis
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) afflicting over 77,000 Canadians. Unfortunately, the therapeutic arsenal to relieve MS symptoms is limited. It is therefore essential to develop better approaches to treat the symptoms of MS. The use of cannabis for recreational purposes is now legal in Canada. However, for many years, people with Multiple Sclerosis (PwMS) have used cannabis either to relax, to reduce pain and spasticity, or to improve sleep and daily functioning. Currently, there is little scientifically established evidence that cannabis works on these symptoms in people with MS. It is therefore important to carry out studies to better understand the efficacy Δ-9-tetrahydrocannabinol (THC), and cannabidiol (CBD) on MS symptoms . THC is known for its analgesic, neuroprotective and anti-inflammatory properties and CBD seems to have positive effects on anxiety and cognitive abilities (memory, concentration).
For this study, investigators hypothesize that administering different doses of THC alone, CBD alone, and THC and CBD combined will result in a significant beneficial effect on spasticity relief compared to placebo.
First Posted: October 25, 2021
Condition(s): Multiple Sclerosis
Intervention(s): Cannabis oil vs placebo
Status: Not yet recruiting
Enrollment (expected or actual): 250
Allocation: Randomized
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
Principal Investigator:
Completion Date (primary or actual): March 15, 2024
CT.gov Identifier: NCT05092191
Evaluation of Oral THC and CBD in Men and Women
The purpose of this study is to determine the pharmacokinetics and pharmacodynamics of oral delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and to evaluate detection of recently smoked THC in oral fluid.
First Posted: October 5, 2021
Condition(s): Drug Abuse, Intoxication by Drug, Impairment
Intervention(s): Placebo, THC, CBD, THC + CBD
Status: Not yet recruiting
Enrollment (expected or actual): 22
Allocation: Randomized
Sponsor: University of California, Los Angeles
Principal Investigator: Ziva D. Cooper, PhD, Associate Professor
Completion Date (primary or actual): November 2023
CT.gov Identifier: NCT05067387
Cannabidiol for Reduction of Brain Neuroinflammation
This study will investigate whether cannabidiol (CBD), the primary centrally and peripherally active non-intoxicating compound in the cannabis plant, exerts anti-neuroinflammatory effects in patients with chronic low back pain (cLBP) with or without mild-to-moderate depression.
First Posted: October 4, 2021
Condition(s): Back Pain, Depressive Symptoms
Intervention(s): CBD, Placebo
Status: Recruiting
Enrollment (expected or actual): 80
Allocation: Randomized
Sponsor: Massachusetts General Hospital
Principal Investigator: Jodi Gilman, Associate Professor
Completion Date (primary or actual): September 1, 2026
CT.gov Identifier: NCT05066308
Safety and Efficacy of Oral Cannabis in Chronic Spine Pain
The overall objectives of this study are to investigate the efficacy of extended cannabis treatment to reduce patient exposure to prescription opioids through its use 1) as a non-opioid analgesic treatment, and 2) as a therapy for reducing high-dose opioid use in patients with chronic spine pain.
First Posted: September 22, 2021
Condition(s): Back Pain, Neck Pain
Intervention(s): THC/CBD, THC, Placebo
Status: Not yet recruiting
Enrollment (expected or actual): 157
Allocation: Randomized
Sponsor: University of Colorado, Denver
Principal Investigator:
Completion Date (primary or actual): June 2024
CT.gov Identifier: NCT05052541
Topical CBD for Musculoskeletal Pain
Rationale: CBD is commonly being used as an over-the-counter treatment for musculoskeletal pain; however, no clinical trial has been performed to establish efficacy of CBD in humans for musculoskeletal pain.
Hypothesis: CBD is more effective than placebo for relieving pain and improving patient-reported outcomes for musculoskeletal pain.
Study Design: The study design with be a double-blind, randomized controlled trial with crossover. Treatment will be blinded to the subjects and investigators. Patients will be randomly assigned 2 weeks of the CBD or control and then crossover to the other condition for 2 additional weeks. Patients will apply the CBD or control cream to the affected area twice daily (approximately every 12 hours) for 1 hour. Subjects will be advised to observe for physiologic changes, skin changes, or other adverse effects.
First Posted: December 28, 2021
Condition(s): Musculoskeletal Pain
Intervention(s): CBD
Status: Not yet recruiting
Enrollment (expected or actual): 100
Allocation: Randomized
Sponsor: University of Virginia
Principal Investigator: Brent DeGeorge, Assistant Professor of Plastic Surgery
Completion Date (primary or actual): June 2022
CT.gov Identifier: NCT05170451
Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
This study will monitor for potential chronic liver injury and liver fibrosis, in participants treated with cannabidiol oral solution.
First Posted: September 16, 2021
Condition(s): Lennox Gastaut Syndrome, Dravet Syndrome, Tuberous Sclerosis Complex
Intervention(s): Cannabidiol
Status: Recruiting
Enrollment (expected or actual): 150
Allocation: N/A
Sponsor: Jazz Pharmaceuticals
Principal Investigator:
Completion Date (primary or actual): August 1, 2027
CT.gov Identifier: NCT05044819